Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma Journal Article
| Authors: | Wirk, B.; Fenske, T. S.; Hamadani, M.; Zhang, M. J.; Hu, Z. H.; Akpek, G.; Aljurf, M. D.; Armand, P.; Ayala, E.; Bachanova, V.; Bolwell, B.; Cairo, M. S.; Cashen, A.; Chen, Y. B.; Costa, L. J.; Farhan, S.; Freytes, C. O.; Gajewski, J. L.; Gibson, J.; Hale, G. A.; Holmberg, L. A.; Hsu, J. W.; Inwards, D. J.; Kamble, R. T.; Maharaj, D.; Maziarz, R. T.; Munker, R.; Nath, R.; Reddy, N. M.; Reeder, C. B.; Rizzieri, D. A.; Sauter, C. S.; Savani, B. N.; Schouten, H. C.; Sureda, A.; Vose, J. M.; Waller, E. K.; Wiernik, P. H.; Gale, R. P.; Burns, L. J.; Saber, W. |
| Article Title: | Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma |
| Abstract: | There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8% (95% confidence interval [CI], 4% to 14%), 5-year progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%). In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality. © 2014 American Society for Blood and Marrow Transplantation. |
| Keywords: | adult; cancer chemotherapy; cancer survival; controlled study; treatment outcome; aged; major clinical study; overall survival; fludarabine; cancer radiotherapy; cytarabine; ibritumomab tiuxetan; rituximab; cancer staging; follow up; cancer immunotherapy; progression free survival; tumor volume; etoposide; cyclophosphamide; melphalan; chemosensitivity; carmustine; acute graft versus host disease; myeloablative conditioning; whole body radiation; karnofsky performance status; allogeneic hematopoietic stem cell transplantation; large cell lymphoma; radioimmunotherapy; hla typing; tositumomab i 131; follicular lymphoma; autologous hematopoietic stem cell transplantation; alemtuzumab; leukemia remission; transplant; human; male; female; article; transformed follicular lymphoma |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 20 |
| Issue: | 7 |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-07-01 |
| Start Page: | 951 |
| End Page: | 959 |
| Language: | English |
| DOI: | 10.1016/j.bbmt.2014.03.014 |
| PROVIDER: | scopus |
| PMCID: | PMC4060436 |
| PUBMED: | 24641828 |
| DOI/URL: | |
| Notes: | Biol. Blood Marrow Transplant. -- Export Date: 8 July 2014 -- CODEN: BBMTF -- Source: Scopus |
